Hoth Therapeutics (NASDAQ:HOTH) Posts Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) posted its quarterly earnings results on Friday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Hoth Therapeutics Stock Down 4.9%

HOTH stock traded down $0.03 during midday trading on Friday, reaching $0.63. 291,498 shares of the company’s stock traded hands, compared to its average volume of 401,654. The company has a market cap of $12.11 million, a price-to-earnings ratio of -0.70 and a beta of 0.57. The firm’s fifty day moving average price is $0.78 and its 200-day moving average price is $0.98. Hoth Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.12.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hoth Therapeutics in a research report on Friday, April 24th. Wall Street Zen downgraded shares of Hoth Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 2nd. Finally, D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.00.

Institutional Trading of Hoth Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lido Advisors LLC grew its stake in shares of Hoth Therapeutics by 100.0% in the 1st quarter. Lido Advisors LLC now owns 39,000 shares of the company’s stock worth $33,000 after acquiring an additional 19,500 shares in the last quarter. DRW Securities LLC bought a new stake in shares of Hoth Therapeutics in the 4th quarter worth $257,000. Geode Capital Management LLC grew its stake in shares of Hoth Therapeutics by 18.0% in the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after acquiring an additional 27,577 shares in the last quarter. Kestra Private Wealth Services LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter worth $51,000. Finally, Citadel Advisors LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter worth $232,000. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.